Tirzepatide became the first dual GLP/GLP-1 receptor agonist to gain FDA approval for treating T2DM in 2022 and obesity in 2023 [ Table 2 ]
Genetic variants in the GLP1R and GIPR genes may provide clinical context about expected response trajectory
Microdosing involves using doses below manufacturer-recommended levels without supporting clinical trial data on efficacy or safety
Access is still an issue for these effective medications. Clare Thompson, MD, a general practitioner who leads weight management services at the Cadogan Clinic in London, agrees
Qian P, Tian H, Wang Y, Lu W, Li Y, Ma T, Gao X, Yao W
Have you ever considered who formulated the supplements youve taken in the past